Navigating and Targeting the Novel Tie2 Signaling Pathway...

455 11th Avenue at 38th Street,New York NY 10001

13 July, 2022

Description

Activity ChairArshad M. Khanani, MD, MA, FASRS Managing Partner Director of Clinical Research Director of Fellowship Sierra Eye Associates Clinical Associate Professor University of Nevada Reno, NV FacultyCaroline R. Baumal, MD, FASRS Professor of Ophthalmology New England Eye Center Tufts University School of Medicine Boston, MA Carl J. Danzig, MD, FASRS Director of Vitreoretinal Services and Retina Clinical Research Rand Eye Institute Deerfield Beach, FL Affiliate Assistant Professor of Clinical Biomedical Science Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, FL OverviewThe angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering treatment burden with the need for fewer treatment injections over time. In this continuing medical education activity, experts in the field examine the role of the Tie2 signaling pathway in the pathophysiology of retinal vascular diseases and assess the latest safety and efficacy of therapies that act on the angiopoietin/Tie2 pathway in patients with retinal vascular diseases. Agenda1:00 PM Registration and Lunch 1:30 PM Introduction and Pretest Arshad M. Khanani, MD, MA 1:35 PM Achieving Vascular Integrity in Retinal Disease Caroline R. Baumal, MD 1:55 PM Retinal Disease, Tie-2 Signaling, and Targeting of Angiopoietin-2: Efficacy and Outcomes Data Carl J. Danzig, MD 2:20 PM Case Presentation: Targeting of Ang-2 in nAMD Arshad M. Khanani, MD, MA 2:25 PM Wheel of Knowledge With your host, Arshad M. Khanani, MD, MA, 2:45 PM Posttest and Question & Answer 3:00 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Recognize that retinal vascular diseases share several key pathophysiologic aspects, including neovascularization, vascular permeability, and inflammation. Examine the role of the Tie2 signaling pathway in the pathophysiology of retinal vascular diseases as well as the history of Tie 2 inhibition. Assess the safety and efficacy of therapeutic strategies that act on the angiopoietin/Tie2 pathway in patients with retinal and choroidal vascular diseases. Target AudienceThe intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal diseases. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group. This program is not affiliated with ASRS. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity. Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.